Additionally, we found that the tumor stem cell markers (CD133 and EpCAM) were both highly expressed in recurrent HCCs compared with initial HCCs (CD133+: 19 vs. 5%, p = 0.002; EpCAM+: 15 vs. 6%, p = 0.005). The gene discussed is PROM1; the disease is neoplasm.